IOVA SECURITIES NOTICE: Did Iovance Biotherapeutics, Inc. Commit Securities Fraud? Contact BFA Law about the Class Action Lawsuit by July 14

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and its senior executives for potential violations of federal securities laws, following disappointing financial results and issues with its melanoma treatment, Amtagvi [1][2][5]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of California, titled Sundaram v. Iovance Biotherapeutics, Inc., et al., No. 25-cv-04177 [2]. - Investors have until July 14, 2025, to request to lead the case [2]. Group 2: Company Background - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. - The company launched its key melanoma treatment, Amtagvi, in February 2024 [3]. Group 3: Issues Leading to the Lawsuit - Iovance claimed that its authorized treatment centers (ATCs) would drive demand for Amtagvi; however, the ATCs faced long timelines for patient treatment and ineffective patient identification, leading to high drop-off rates [4]. - The company reported disappointing financial results for Q1 2025, revising its full-year 2025 revenue guidance due to slow treatment timelines and high patient drop-off rates [5]. Group 4: Stock Market Reaction - Following the announcement of poor financial results, Iovance's stock price fell over 44%, from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025 [6].